Evidence map›Paper›PMID 39339421›Full record

ArticleMolecules (Basel, Switzerland)2024

Preparation, Evaluation, and Bioinformatics Study of Hyaluronic Acid-Modified Ginsenoside Rb1 Self-Assembled Nanoparticles for Treating Cardiovascular Diseases.

Lixin Du, Yifei Xiao, Qidong Wei, Zhihua Guo, Ya Li

Abstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. How Advanced Is Nanomedicine for Atherosclerosis?International journal of nanomedicine · 2025
    Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Lixin DuSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Yifei XiaoSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Qidong WeiSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.
Zhihua GuoSchool of Chinese Medicine, Hunan University of Chinese Medicine, Changsha 410208, China.
Ya LiSchool of Pharmacy, Hunan University of Chinese Medicine, Changsha 410208, China.ORCID 0009-0005-8684-9308

Funding

Hunan University students innovation and entrepreneurship training program S202310541090Key Discipline Project on Chinese Pharmacology of Hunan University of Chinese Medicine 202302National Natural Science Foundation of China 82174343Postgraduate Scientific Research Innovation Project of Hunan Province CX20230830Scientific Research Topics of Hunan Provincial Health and Wellness Commission D202303017861
6 · The paper itself

Abstract

(1) Objective: To optimize the preparation process of hyaluronic acid-modified ginsenoside Rb1 self-assembled nanoparticles (HA@GRb1@CS NPs), characterize and evaluate them in vitro, and investigate the mechanism of action of HA@GRb1@CS NPs in treating cardiovascular diseases (CVDs) associated with inflammation and oxidative stress. (2) Methods: The optimal preparation process was screened through Plackett-Burman and Box-Behnken designs. Physical characterization of HA@GRb1@CS NPs was conducted using transmission electron microscopy, Fourier-transform infrared spectroscopy, X-ray diffraction, and differential scanning calorimetry. Stability experiments, in vitro drug release studies, and lyophilisate selection were performed to evaluate the in vitro performance of HA@GRb1@CS NPs. The anti-inflammatory and antioxidant capabilities of HA@GRb1@CS NPs were assessed using H9c2 and RAW264.7 cells. Additionally, bioinformatics tools were employed to explore the mechanism of action of HA@GRb1@CS NPs in the treatment of CVDs associated with inflammation and oxidative stress. (3) Results: The optimal preparation process for HA@GRb1@CS NPs was achieved with a CS concentration of 2 mg/mL, a TPP concentration of 2.3 mg/mL, and a CS to TPP mass concentration ratio of 1.5:1, resulting in a particle size of 126.4 nm, a zeta potential of 36.8 mV, and a PDI of 0.243. Characterization studies confirmed successful encapsulation of the drug within the carrier, indicating successful preparation of HA@GRb1@CS NPs. In vitro evaluations demonstrated that HA@GRb1@CS NPs exhibited sustained-release effects, leading to reduced MDA (Malondialdehyde) content and increased SOD (Superoxide Dismutase) content in oxidatively damaged H9c2 cells. Furthermore, it showed enhanced DPPH (2,2-Diphenyl-1-picrylhydrazyl) and ABTS

Indexed as

AntioxidantsCardiovascular DiseasesGinsenosidesHyaluronic AcidNanoparticlesAnimalsAnti-Inflammatory AgentsCell LineCell SurvivalComputational BiologyDrug CarriersDrug LiberationMiceOxidative StressRatsRAW 264.7 CellsAnti-Inflammatory AgentsAntioxidantsDrug Carriersginsenoside Rb1GinsenosidesHyaluronic Acidbioinformaticscardiovascular diseasesginsenoside Rb1inflammationoxidative stressself-assembled nanoparticles

Identifiers

PMID39339421
PMCPMC11433718

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.